https://scholars.lib.ntu.edu.tw/handle/123456789/637413
標題: | Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial | 作者: | Goto, Koichi Goto, Yasushi Kubo, Toshio Ninomiya, Kiichiro Kim, Sang-We Planchard, David Ahn, Myung-Ju Smit, Egbert F de Langen, Adrianus Johannes Pérol, Maurice Pons-Tostivint, Elvire Novello, Silvia Hayashi, Hidetoshi Shimizu, Junichi Kim, Dong-Wan Kuo, Chih-Hsi CHIH-HSIN YANG Pereira, Kaline Cheng, Fu-Chih Taguchi, Ayumi Cheng, Yingkai Feng, Wenqin Tsuchihashi, Zenta Jänne, Pasi A |
公開日期: | 1-十一月-2023 | 卷: | 41 | 期: | 31 | 來源出版物: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 摘要: | Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2-mutant (HER2m; defined as single-nucleotide variants and exon 20 insertions) metastatic non-small-cell lung cancer (mNSCLC). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/637413 | ISSN: | 0732183X | DOI: | 10.1200/JCO.23.01361 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。